Propagation of organoids from urology tumors

• Conditions: rothelial carcinoma, renal cancer, prostata cancer, penile cancer; C60; C61; C64; C65; C66; C67; C68; Malignant neoplasm of penis; Malignant neoplasm of prostate

• Registration Number: DRKS00030035
• Lead Sponsor: niversitätsklinikum Ulm, Klinik für Urologie und Kinderurologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-13
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Informed consent of the patient

Exclusion Criteria

Decline by the patient

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the propagation of organoids from metastatic tumors per se.

Secondary Outcome Measures

Name	Time	Method
Secondary endpoints include proteome-, genome-, transcriptome-, epigenome- analysis as well as compound testings on the organoids.